Newsletter

Pol. Merkur. Lek (Pol. Med. J.), 2015, XXXVIII/224: 100-103 Maximize

Pol. Merkur. Lek (Pol. Med. J.), 2015, XXXVIII/224: 100-103

Title: Chromophobe renal cell carcinoma – case report 

Authors: Krawiec K, Marks P, Różański W, Lipiński M

More details

07/224

40,00 zł

SUMMARY IN POLISH & ENGLISH. FULL ARTICLE ONLY IN POLISH.

Chromophobe renal cell carcinoma – case report


Krawiec K1, Marks P1, Różański W2, Lipiński M2.

1Division of Urology Regional Hospital John Paul II in Bełchatów; 2Department of General, Oncologic and Functional Urology – II Department of Urology, Medical University of Łódź, Poland

Malignant tumors of the kidney, which the most common is renal cell carcinoma (RCC) is diagnosed in Poland in more than 5,000 patients each year. Most cases of kidney cancer occurs after the age of 55 years. In men, the risk is 2 times higher than in women. Among the various histological subtypes of RCC, 5% of cases of chromophobe renal cell carcinoma (chRCC). The 1% is in combination with oncocytoma, creating a hybrid chromophobe renal cell carcinoma. The paper presents a case report of a patient operated on because of a kidney tumor – eosinophilic type of chromophobe cancer. During subsequent care of patients experienced a rare complication of this type of tumor, ie. metastasized to the paraaortic lymph nodes. Another surgery and radiotherapy were later stages of treatment. Discussed in the paper example of a patient with type eosinophilic chRCC indicate the variable nature and mileage as compared with typical of the tumor, thus requiring increased surveillance oncology. This requires a careful approach clinicians at the stage of diagnosis and then treatment and aftercare.

Key words: chromophobe renal cell carcinoma, tyrosine kinase inhibitor, hybrid chromophobe cancer, oncocytoma

Pol Med J, 2015; XXXVIII (224); 100–103